TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in attenuating pY705-STAT3 phosphorylation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. To date, TTI-101 is well tolerated and has clinical activity in a first-in-man Phase 1 study in patients with advanced solid tumors.

For more information on the ongoing clinical trials of TTI-101, please visit our clinical trials page.

TTI-102 and TTI-109 are next generation orally bioavailable, small molecule STAT3 inhibitors that are structurally related to, yet chemically distinct from TTI-101. TTI-102 and TTI-109 have demonstrated key characteristics for clinical use including tolerability, bioavailability, and potency in preclinical studies.

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.